News

<p>The acquisition bolsters PolyPeptide Laboratories&#0039; manufacturing capacity and capabilities, from small-scale custom peptides for research to large-scale peptides for therapeutic applications. Such capabilities complement the group&#0039;s long-established core

<p>Under the terms of the agreement, Alios will provide Cleveland Clinic an upfront license fee, various development, regulatory and commercial milestones, and royalties on net sales. In addition,

In the initial dose escalation Phase of the trial, 15 patients were treated sequentially in four dose cohorts with escalating doses of radiolabeled TM-601. Because no dose-limiting toxicities

This study will be a randomized, examiner-blinded, parallel design trial comparing three different doses of PAC-113 to Nystatin, a topical mouth rinse treatment for oral candidiasis. The study

The objectives of the study were to define the safety profile and maximum tolerated dose of RAV12, to define the pharmacokinetics and describe preliminary efficacy. Treatment with RAV12

This new study is expected to provide the first assessment of TPI 1020’s potential activity in COPD. The trial is a 6-week, multi-center, double blind, placebo and active-controlled

Each study will evaluate the efficacy of ofatumumab in reducing the clinical signs and symptoms in RA patients after a single course of ofatumumab and are comprised of

The US District Court of California has issued a ruling in favor of the company, affirming that its intellectual property rights for the Microcyn technology are enforceable. In

The patent relates to the combined use of a cardiac marker of cell injury, such as Troponin I, with a marker of organ adaptation, such as brain natriuretic